Juzentaihoto reduces post-partial hepatectomy hyperammonemia by stabilizing intestinal microbiota

Journal of Traditional Medicines

Volumn 23, Issue 6, 2006, Pages 208-215

  Imazu, Yoshihiro ^a,b   Tsuiji, Kenji ^a   Toda, Takahiro ^a,c   Ishige, Atsushi ^a   Sugiyama, Kiyoshi ^c   Benno, Yoshimi ^d   Watanabe, Kenji ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d RIKEN BIORESOURCE CENTER   (Japan)

Author keywords

hepatectomy; hyperammonemia; intestinal microbiota; Juzentaihoto (JTX); Kampo medicine; terminal restriction fragment length polymorphism (T RFLP)

Indexed keywords

EID: 34249908290     PISSN: 18801447     EISSN: 18813747     Source Type: Journal    
DOI: 10.11339/jtm.23.208     Document Type: Article

References (37)

1. Gansz, R., Swain, M., Traber, P. DalCanto, M., Butterworth, RF. and Blei, AT.: Ammonia-induced swelling of rat cerebralcorticol slices; implications for the pathogenesis of brain edema in acute failure. Metab. Brain Dis., 4, 213-223, 1989.
2. Iber, F.L., Chalmers, T.C., Stowers, B., Fryar, A., Link, A.M.: Biochemical observations on the use of L-glutamic acid in the treatment of hepatic coma. J Clin Invest., 36, 706-712, 1957.
3. Scharschmidt, B. F. in Cecil Textbook of Medicine (J.B. Wyngaarden, L. H. Smith, and J. C. Bennett, Eds.) Saunders, Tokyo, Japan, pp.796-799, 1992.
4. Dai, Y., Kato, M., Takeda, K., Kawamoto, Y., Akhand, A. A., Hossain, K., Suzuki, H. and Nakashima, I.: T-cell-immunity-based inhibitory effects of orally administered herbal medicine juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice. J Invest Dermatol., 117, 694-701, 2001.
5. Saiki, I.: A Kampo medicine “Juzen-taiho-to” -prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull., 23, 677-688, 2000.
6. Salzman, N. H., de Jong, H., Paterson, Y., Harmsen, H. J., Welling, G. W. and Bos, N. A.: Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology 148, 3651-3660, 2002.
7. Higgins, G. M. and Anderson, R. M.: Experimental pathology of the liver. Arch. Pathol, 12, 186-202, 1931.
8. Kibe, R., Sakamoto, M., Hayashi, H., Yokota and H., Benno, Y.: Maturation of the murine cecal microbiota as revealed by terminal restriction fragment length polymorphism and 16S rRNA gene clone libraries. FEMS Microbiol Lett 235, 139-146, 2004.
9. McDermott, W.V.: Metabolism and toxicity of ammonia. N Engl J Med, 257, 1076-1081, 1957.
10. Angela, J.V. and Sigrid, M.B.: Ammonia production by intestinal bacteria: The effects of lactose, lactolose and glucose. J. Med. Microbiol, 13, 177-191, 1980.
11. Gansz, R., Swain, M. and Traber, P.: Ammonia-induced swelling of rat cerebral cortical slices: implications for the pathogenesis of brain edema in acute hepatic failure. Metab. Brain Dis, 4, 213-223, 1989.
12. Lai, J.C.K. and Cooper, A.J.: Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J Neurochem, 47, 1376-1386, 1986.
13. Hindelt, B., Flum, F. and Duffy, T.E.: Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest, 59, 386-396, 1977.
14. Parry-Billings, M., Leighton, B., Dimitriadis, G., de Vasconcelos, P.R. And Newsholme, E.A.: Skeketal muscle glutamine metabolism during sepsis in the rat. Int J Biochem, 21, 419-423, 1989.
15. van Leeuwen, P.A., Hong, R.W., Rounds, J.D., Rodrick, M.L. and Wilmore, D.: Hepatic failure and coma after liver resection in reversed by manipulation of gut contents. The role of endotoxin. Surgery, 110, 169-174, 1991.
16. Qing, L., Zhong, P, D., Da, K, H., Stig, B.k, Jelica, K., and Stephen, M.R.: Synbiotic Modulation of Gut Flora: Effect on Minimal Hepatic Encephalopathy in Patients With Cirrhosis. HEPATOLOGY, 39, 1441-1449, 2004.
17. Conn, H.O., Leevy, C.M., Vlahcevic, Z.R., Rodgers, Jb., Maddrey, W.C., Seeff, L. and Levy, L.L.: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology, 72, 573-583, 1977.
18. Park, C, H., Joo, Y, E., Kim, H, S., Choi, S, K., Rew, J, S. and Kim, S, J.:Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient. J Korean Med Sci., 20, 150-152, 2005.
19. Campillo, B., Pernet, P., Bories, P., N., Richardet, J, P., Devanlay, M. and Aussel C.: Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol., 11, 755-759, 1999.
20. Parini, P., Cipolla, A., Ronchi, M., Salzetta, A., Mazzella, G. and Roda, E.: Effect of rifaximin and paramomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res, 52, 34-49, 1992.
21. Morgan, M.H., Read, A.E. and Speller, D.C.E.: Treatment of hepatic encephalopathy with metroni-dazole. Gut, 23, 1-7, 1982.
22. Tarao, K., Ikeda, T., Hayashi, K. and Sakurai I.: A Suc-cessful use of vancomycin hydrochloride in thetreatment of lactulose-resistant chronic hepatic encephalopathy. J Gastroenterol Hepatol, 4, 284-286, 1989.
23. Berk, D.P. And Chalmers, T.: Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med, 73, 393-396, 1970.
24. Guo, F. C., Kwakkel, R. P., Williams, B. A., Li, W. K., Li, H. S., Luo, J. Y., Li, X. P., Wei, Y. X., Yan, Z. T. and Verstegen, M. W.: Effects of mushroom and herb polysaccharides, as alternatives for an antibiotic, on growth performance of broilers. Br Poult Sci., 45, 684-694, 2004.
25. Yan, X., Kita, M., Minami, M., Yamamoto, T., Kuriyama, H., Ohno, T., Iwakura, Y. and Imanishi, J.: Antibacterial effect of Kampo herbal formulation Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang) on Helicobacter pylori infection in mice. Microbiol Immunol, 46, 475-482, 2002.
26. Didry, N., Dubreuil, L. and Pinkas, M.: Activity of thymol, carvacrol, cinnamaldehyde and eugenol on oral bacteria. Pharm Acta Helv, 69, 25-28, 1994.
27. Tan, B. K. and Vanitha, J.: Immunomodulatory and antimicrobial effects of some traditional chinese medicinal herbs: a review. Curr Med Chem. 11, 1423-1430, 2004.
28. Ishihara, M., Homma, M., Kuno, E., Watanabe, M. and Kohda, Y.: Combination use of kampo-medicines and drugs affecting intestinal bacterial flora. Yakugaku Zasshi, 122, 695-701, 2002.
29. Hayashi, H., Sakamoto, M. and Benno, Y.: Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol, 46, 535-548, 2002.
30. Suau, A., Bonnet, R., Sutren, M., Godon, J. J., Gibson, G. R., Collins, M. D. and Dore, J.: Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol, 65, 4799-4807, 1999.
31. Benno, Y., Shiragami, N., Uchida, K., Yoshida, Tadashi. and Mitsuoka T.: Effect of moxalactam on human fecal microflora. Antimicrob. Agents chemother. 29, 175-178, 1986.
32. Bergan, T., Delin C., Johansen, S., Kolstad I.M., Nord C. D. and Thorsteinsson, S. B.: Pharmacokinetics of ciproxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob. Agents chemother. 29, 298-302, 1986.
33. Abreu, M. T., Fukata, M. and Arditi, M.: TLR signaling in the gut in health and disease. J. Immunol. 174, 4453-4460, 2005.
34. Hooper, L.V., Wong, M.H., Thelin, A., Hansson, L., Falk, P.G. and Gordon, J.I.: Molecular analysis of commensal host-microbial relationships in the intestine. Science, 291, 881-884, 2001.
35. Tarao, K.: Prevention of development of hepatocellular carcinoma from HCV associated liver cirrhosis by multi-agents therapy including stronger-neo-minnophagen C. Nippon Rinsho. 59, 769-773, 2001.
36. Syo, Y., Fujisaki, K., Sakashita, H., Yamaguchi, K., Tahara, K., Kubozono, O., Ido A. and Tsubouchi, H.: Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol, 39, 1202-1204, 2004.
37. Rino, Y., Tarao, K., Morinaga, S., Ohkawa, S., Miyakawa, K., Hirokawa, S., Masaki, T., Tarao, N., Yukawa, N., Saeki, H., Takanashi, Y. and Imada, T.: Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res., 26, 2221-2226, 2006.